35 results about "Intravenous route" patented technology

Specific Cytokine Antagonists, including TNF antagonists and / or Interleukin-1 antagonists, are used as novel therapeutic agents for the treatment of hearing loss, including presbycusis and other forms of sensorineural hearing loss. The present invention provides a method for inhibiting the action of TNF and / or IL-1 antagonists for treating hearing loss in a human by administering a TNF antagonist and / or an IL-1 antagonist for reducing the inflammation affecting the auditory apparatus of said human, or for modulating the immune response affecting the auditory apparatus of said human, by administering a therapeutically effective dosage level to said human of a TNF antagonist and / or an IL-1 antagonist. Administration may be systemic, through the subcutaneous, intramuscular, oral, or intravenous routes; or by delivering an anatomically localized application in the region of the head. The TNF antagonist is selected from the group consisting of etanercept, infliximab, D2E7, CDP 571, or thalidomide; and the IL-1 antagonist is either IL-1 RA or IL-1R type II receptor. Antiviral agents may be added for treating certain patients.

The invention discloses a needle component which comprises a transparent or semi-transparent shell. The shell comprises a fluid inlet end portion, a fluid outlet end portion, a flashing flow cavity and an aerating mechanism. The aerating mechanism is arranged among the fluid inlet end portion, the fluid outlet end portion and the flashing flow cavity. An inlet sleeve and an outlet sleeve which are approximately axially aligned extend from the shell and are communicated with the cavity. A sealable sleeve covers the outer end portion of the outlet sleeve. The relative volumes of the sleeves, the cavity and the sealable sleeve are selected to provide rapid and reliable flashing flow indications for intravenous routes. An internal aerating element is positioned in the shell to enable the inner portion to be divided into a first cavity and a second cavity. The second cavity is suitable for keeping negative pressure inside relative to an external environment so as to prevent blood from leaking from a needle when the needle is withdrawn from a patient.

Injectable formulations of water-soluble salts of diclofenac, which cause significantly less pain at the site of injection and can be administered by intradeltoid route, in addition to intragluteal and slow intravenous route.

The subject invention demonstrates a novel antibacterial activity for 2-phenyl-1,2-benzisoselenazol-3(2H)-one 1-oxide, commonly referred to as ebselen se-oxide, and is directed to the treatment of bacterial infections by administration of an effective amount of said compound. Bacterial infections include those infections which are either systemic or superficial in nature. The treatment is intended for a variety of animals, such as premature neonates to adult humans. Administration of ebselen se-oxide to treat superficial bacterial infections may be performed by a topical application, such as via an ointment, a spray, a cream, a mouth wash, an eye drop solution, an ear drop solution, a soap, a gel, or a lotion. In addition, an antibacterial capsule can be administered orally or intravaginally. Administration of ebselen se-oxide to treat systemic bacterial infections may be performed by an intravenous route, a rectal route, an intranasal route, an oral route, an intramuscular route, or by inhalation. Administration of said compound may also be achieved via aerosol, which can be generated by a nebulizer. Ebselen se-oxide may be administered alone, or with a carrier such as dimethylsulfoxide (DMSO), an alcohol, or other suitable carrier. The effective daily amount of ebselen se-oxide is from about 1 μg / kg to 10 mg / kg of body weight.

The present invention provides injectable formulations of water-soluble salts of diclofenac in single doses of less than 2 ml, which cause significantly less pain at the site of injection and can be administered by intradeltoid route, in addition to intragluteal and slow intravenous route. More specifically the injectable preparations contain 75 mg to 100 mg of water-soluble salts of diclofenac, in about 1 ml injection solution without significantly raising the viscosity of the injection solution without the use surfactants. The formulations are adjusted to pH 6 to 10 containing up to 100 mg of diclofenac salt in a medium comprising of water, along with one or more co-solvent(s) / solubilizer(s), antioxidants, preservatives, buffers, alkali and stabilizers.

The invention relates to the field of nanometer drug carriers, and concretely relates to an asymmetric magnetic mesoporous silica rod supporting chemotherapeutic and gene drugs and application thereof to tumor diagnosis and treatment. The asymmetric magnetic mesoporous silica rod is prepared by employing spherical magnetic ferrite nanoparticles and ethyl orthosilicate through a sol-gel method, and the asymmetric magnetic mesoporous silica rod is subjected to surface functionalization modification, and is successively loaded with a chemotherapeutic drug, coated by a positive high-molecular polymer and loaded with a gene drug, so that a target product is obtained. The chemotherapeutic drug is connected with the silica rod through functionalization of the mesoporous surface, and the silica rod is endowed with the pH-responsive drug release characteristic, also the biocompatibility of the composite material is increased and the in-vivo cycling time is prolonged, and gene is supported in an electrostatic adsorption mode. The composite material is injected into a living body via an intravenous route, the characteristics of nanoparticle in-vivo passive targeting, gene guiding and pH-responsive drug release of the composite material are utilized, also the cooperativity of the multidrug resistant gene and the chemotherapeutic drug is utilized, and in-vitro magnetic targeting, NMR imaging and other technologies are applied to diagnosis and treatment of malignant tumors.

This invention describes how to modify a fibrin-binding protein, such as tPA, with a contrast agent, such as iodine. This substance could then be given to a patient suspected of having a blood clot by an intravenous route, and then detected by a radiographic study at a short pre-determined time later. Appropriate therapy is started immediately as determined by the radiographic study.

The invention provides a [dichloro-1,2-cyclohexanediamine]platinum complex, and the complex is obtained from the complex reactions between dichloro-1,2-cyclohexanediamine and a polymer which has the structure of the formula (I). The [Dichloro-1,2-cyclohexanediamine]platinum has a cyclohexanediamine structure, a stable inner-core structure is formed because of the accumulation and hydrophobic effect after the [Dichloro-1,2-cyclohexanediamine]platinum cooperate with a polymer, and the stability of the [Dichloro-1,2-cyclohexanediamine]platinum is good under physiology conditions. The complex can effectively avoid the problems of sudden release and non-specific interaction of [Dichloro-1,2-cyclohexanediamine]platinum after [Dichloro-1,2-cyclohexanediamine]platinum enters the blood circulation system through intravenous route. The complex can be assembled to form a micelle structure; accumulation of the complex on the tumor locations can be achieved through strengthening osmotic and retention effects, and thus the goals of reducing toxic and by effects and improving curative effects are achieved. Furthermore, the adopted complex has a good biological compatibility, is capable of degrading in human bodies, and thus the prepared [Dichloro-1,2-cyclohexanediamine]platinum has a good solubility.

The present invention discloses chonsurid preparation capable of being used for venous injection and its preparation process. The purified chonsurid preparation may be used for intramuscular injection and intravenous injection after being added into glucose solution or physiological saline, and has convenient use. Owing to the raised purity of chonsurid, the chonsurid preparation may be injected directly into blood circulation system resulting in high blood medicine concentration, fast acting, high curative effect and less side effect.

The invention provides the application of 20(S)-ginsenoside-Rg3 in the preparation of medicines for treating or preventing hypertension, and the invention also provides a pharmaceutical composition containing 20(S)-ginsenoside-Rg3, the pharmaceutical composition Administration can be by oral, sublingual, transdermal, intramuscular, subcutaneous or intravenous routes.

The invention discloses a needle component which comprises a transparent or semi-transparent shell. The shell comprises a fluid inlet end portion, a fluid outlet end portion, a flashing flow cavity and an aerating mechanism. The aerating mechanism is arranged among the fluid inlet end portion, the fluid outlet end portion and the flashing flow cavity. An inlet sleeve and an outlet sleeve which are approximately axially aligned extend from the shell and are communicated with the cavity. A sealable sleeve covers the outer end portion of the outlet sleeve. The relative volumes of the sleeves, the cavity and the sealable sleeve are selected to provide rapid and reliable flashing flow indications for intravenous routes. An internal aerating element is positioned in the shell to enable the inner portion to be divided into a first cavity and a second cavity. The second cavity is suitable for keeping negative pressure inside relative to an external environment so as to prevent blood from leaking from a needle when the needle is withdrawn from a patient.